| Symbol | DSKYF |
|---|---|
| Name | DAIICHI SANKYO CO., LTD. |
| Sector | UNDEFINED |
| Region | Asia |
| Industry | - |
| Address | 103-8426 Japan 3-5-1 nibonbashi_Honcho Chuo-ku |
| Telephone | 891-3-6225-1111 |
| Fax | — |
| — | |
| Website | http://www.daiichisankyo.com |
| Incorporation | JP |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 3/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Tokyo Stock Exchange |
| CIK | 0001340156 |
| Description | Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (Olmetec®), launched in 2002 by Sankyo and now available in more than 50 countries around the world; the antiplatelet agent prasugrel (Efient®), launched in 2009 for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); and edoxaban (Lixiana®), the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism (VTE). Additional info from OTC: |
No news found.